Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.94
+0.18 (+1.22%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
April 05, 2023
Millions of people are scrambling to get their ADHD medication. Here's why.
Via
Investor's Business Daily
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
April 04, 2023
B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...
Via
Benzinga
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
March 27, 2023
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.
Via
Investor's Business Daily
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
March 25, 2023
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...
Via
Talk Markets
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
March 20, 2023
Via
Benzinga
Zoetis Stock Shows Rising Relative Strength Upgrades
February 17, 2023
Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
Via
Investor's Business Daily
Current Report: Takeda Pharmaceutical (TAK)
January 23, 2023
In the past year, Takeda’s share price increased by $1.73, or about 12%.
Via
Talk Markets
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
March 16, 2023
Via
Benzinga
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
March 15, 2023
Via
Benzinga
Should You Give Up on Novavax?
March 03, 2023
After a spectacular 2020 performance, Novavax's shares have plummeted.
Via
The Motley Fool
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
March 02, 2023
The FDA made a bold move in the CRISPR gene-editing realm.
Via
Investor's Business Daily
A Bullish Sign Appears On Takeda Pharmaceutical's Chart
December 28, 2022
Via
Benzinga
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
December 13, 2022
Via
Benzinga
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
February 28, 2023
These two high-yield dividend stocks are trading at bargain-basement prices.
Via
The Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
February 21, 2023
Via
Benzinga
Is This the Telltale Sign to Sell Novavax Stock?
February 14, 2023
You won't find Novavax's latest bad news trumpeted in a press release.
Via
The Motley Fool
NeurAxis: Should You Buy This IPO?
February 08, 2023
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
Via
Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
February 06, 2023
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
Via
Talk Markets
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
February 02, 2023
Via
Benzinga
7 Sorry Dividend Stocks to Sell in February Before It’s Too Late
January 30, 2023
These dividend stocks to sell have weak underlying fundamentals, offering little upside potential ahead for investors.
Via
InvestorPlace
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Via
Talk Markets
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
January 24, 2023
Via
Benzinga
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
January 14, 2023
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...
Via
Talk Markets
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
January 09, 2023
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
December 14, 2022
Via
Benzinga
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities?
November 30, 2022
Tech layoffs are in the news, but life sciences companies seem to be doing better.
Via
The Motley Fool
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.